TECH vs ILMN vs RVTY Stock Comparison

Bio-Techne, Illumina and Revvity Prices as of Oct 26, 2026 Peers: Industry group
TECH BIO-TECHNE Corp
$72.69 +0.1% 1M +10.3% 1Y
Market cap
$11.32B
P/E
62.3x
Revenue (TTM)
$1.22B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins
ILMN Illumina, Inc.
$271.04 +0.4% 1M +170.7% 1Y
Market cap
$42.23B
P/E
51.2x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
6 wins
RVTY Revvity, Inc.
$160.32 +6.1% 1M +62.1% 1Y
Market cap
$18.07B
P/E
76.0x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
3 wins

Head to Head

12 decided of 12

Illumina leads on 6 of the 12 questions below (Illumina 6, Revvity 3, Bio-Techne 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTECHILMNRVTYLeader
Larger companyMarket capitalisation $11.32B $42.23B $18.07B ILMN
Cheaper on earningsLower P/E, profitable companies only 62.3x 51.2x 76.0x ILMN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 33.7x 54.3x 31.4x RVTY
Faster revenue growthRevenue growth, trailing twelve months -0.4% +4.9% +4.1% ILMN
More profitableNet margin, trailing twelve months 15.0% 18.4% 8.2% ILMN
Better return on capitalReturn on invested capital 8.3% 15.1% 3.1% ILMN
Less leveragedLower net debt / EBITDA -0.2x 0.7x 2.8x TECH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% TECH
Better 1-year returnPrice return, last 12 months +10.3% +170.7% +62.1% ILMN
Better 5-year returnAnnualised price return, 5 years -10.6%/yr -7.5%/yr -1.6%/yr RVTY
Less volatileAnnualised volatility, 1 year 43.6% 50.4% 39.9% RVTY
Higher overall scoreMean of the five percentile scores vs peers 66/100 65/100 58/100 TECH

Percentile Scorecard

TECHILMNRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTECHILMNRVTY
Valuation 58 #96 of 228 52 #111 of 228 68 #73 of 228
Growth 39 #136 of 221 44 #124 of 221 27 #161 of 221
Profitability 94 #14 of 208 97 #7 of 208 79 #45 of 208
Financial Health 86 #35 of 239 51 #118 of 239 47 #128 of 239
Shareholder Returns 52 #67 of 137 84 #23 of 137 69 #43 of 137
Overall 66 65 58
  • TECH ranked among 248 companies in Medical Devices and Diagnostics
  • ILMN ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTECHILMNRVTYSPY
1 month +0.1%+0.4%+6.1% -0.8%
3 months +1.5%+43.1%+48.4% +3.5%
6 months +31.9%+110.9%+84.7% +7.0%
Year to date +23.6%+106.6%+65.7% +12.2%
1 year +10.3%+170.7%+62.1% +13.0%
3 years +22.1%+155.1%+63.8% +86.3%
3 years, per year +6.9%+36.7%+17.9% +23.1%
5 years -43.0%-32.4%-7.8% +68.6%
5 years, per year -10.6%-7.5%-1.6% +11.0%
10 years +186.5%+99.1%+216.8% +258.0%
10 years, per year +11.1%+7.1%+12.2% +13.6%

Risk

MeasureTECHILMNRVTYSPY
Volatility, 1Y 43.6%50.4%39.9% 12.7%
Downside volatility, 1Y 43.6%39.1%35.7% 12.7%
Beta vs S&P 500, 1Y 0.770.811.22 1.00
Return / volatility, 1Y 0.243.391.56 1.02
Max drawdown, 5Y -67.0%-82.9%-59.2% -25.4%
From 52-week high 0.0%-7.7%0.0% -1.8%
52-week high $72.69$293.69$160.32 $779.14
52-week low $43.30$95.03$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTECHILMNRVTY
P/E now vs peer median 62.3xmedian 30.6x 49.6xmedian 30.6x 75.3xmedian 30.6x
P/S now vs peer median 9.3xmedian 3.0x 9.1xmedian 3.0x 6.1xmedian 3.0x
EV/EBITDA now vs peer median 32.3xmedian 17.5x 36.2xmedian 17.5x 25.9xmedian 17.5x
P/FCF now vs peer median 43.1xmedian 23.3x 44.0xmedian 23.3x 31.4xmedian 23.3x
P/B now vs peer median 5.4xmedian 2.4x 14.4xmedian 2.4x 2.5xmedian 2.4x
PEG now vs peer median -4.77median 0.87 1.65median 0.87 -2.42median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTECHILMNRVTY
Revenue $1.22B $4.49B $2.91B
Gross profit $799.07M $2.98B $1.60B
Operating income $251.89M $882.00M $358.85M
Net income $181.86M $825.00M $237.55M
Free cash flow $263.22M $931.00M $568.85M
R&D $94.77M $960.00M $215.83M
EPS (diluted) $1.16 $5.39 $2.13
Cash & equivalents $264.71M $1.04B $1.02B
Total debt $200.00M $1.99B $3.21B
Shares (diluted) 157.01M 153.00M 111.63M
Enterprise value $10.53B $36.99B $14.33B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTECHILMNRVTY
P/E 62.3x 49.6x 75.3x
P/FCF 43.1x 44.0x 31.4x
P/Operating cash flow 38.8x 37.4x 28.0x
P/S 9.3x 9.1x 6.1x
P/B 5.4x 14.4x 2.5x
P/Tangible book 6.3x 16.9x 3.6x
EV/EBITDA 32.3x 36.2x 25.9x
EV/EBIT 44.8x 47.3x 55.9x
EV/Revenue 9.3x 9.3x 6.9x
EV/FCF 42.9x 44.8x 35.3x
EV/Operating cash flow 38.6x 38.1x 31.4x
PEG (3Y EPS CAGR) -4.77 1.65 -2.42

Growth

14 metrics
MetricTECHILMNRVTY
Revenue growth (1Y) -0.4% 4.9% 4.1%
Revenue CAGR (3Y) 2.2% -1.0% 0.9%
Gross profit growth (1Y) 1.1% 4.6% 2.3%
Gross profit CAGR (3Y) 1.3% 2.9% -0.4%
Operating income growth (1Y) 146.3% -31.8% -5.5%
Operating income CAGR (3Y) -5.5% 28.3% -3.7%
Net income growth (1Y) 147.8% -34.4% -16.7%
Net income CAGR (3Y) -14.0% 30.0% -33.8%
EPS growth (1Y) 152.0% -32.7% -12.3%
EPS CAGR (3Y) -13.1% 30.1% -31.2%
Operating cash flow growth (1Y) 1.6% -5.1% 6.2%
Operating cash flow CAGR (3Y) 4.7% 38.1% 86.9%
Free cash flow growth (1Y) 2.6% -9.7% 9.5%
Free cash flow CAGR (3Y) 6.8% 105.0% 64.8%

Profitability

14 metrics
MetricTECHILMNRVTY
Gross margin 65.8% 66.4% 55.0%
EBITDA margin 28.7% 25.7% 26.6%
Operating margin 20.7% 19.6% 12.3%
Pretax margin 19.8% 22.6% 9.0%
Net margin 15.0% 18.4% 8.2%
FCF margin 21.7% 20.7% 19.5%
Operating cash flow margin 24.0% 24.4% 21.9%
Return on equity 8.7% 29.9% 3.3%
Return on assets 7.1% 12.5% 2.0%
Return on invested capital 8.3% 15.1% 3.1%
Return on capital employed 10.5% 17.5% 3.3%
Asset turnover 0.5x 0.7x 0.2x
Cash conversion (OCF / net income) 1.6x 1.3x 2.7x
Stock comp / revenue 0.5% 5.9% 0.8%

Financial Health

11 metrics
MetricTECHILMNRVTY
Debt / assets 7.7% 29.9% 26.6%
Debt / equity 0.1x 0.7x 0.4x
Net debt / EBITDA -0.2x 0.7x 2.8x
Debt / FCF 0.8x 2.1x 5.6x
Liabilities / assets 18.5% 57.3% 40.0%
Equity / assets 81.5% 42.7% 60.0%
Interest coverage 26.2x 8.9x 3.7x
Current ratio 4.5x 1.8x 1.8x
Quick ratio 2.9x 1.2x 1.4x
Cash ratio 1.6x 0.7x 0.8x
Altman Z-score 15.91 7.77 3.38

Shareholder Returns

7 metrics
MetricTECHILMNRVTY
Dividend yield 0.4% – 0.2%
Net buyback yield -0.3% 1.2% 2.6%
Shareholder yield 0.1% 1.2% 2.8%
Payout ratio (earnings) 27.4% – 13.4%
Payout ratio (FCF) 19.0% – 5.6%
Dividend growth (1Y) -0.9% – -6.3%
Dividend CAGR (3Y) -0.2% – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTECHILMNRVTY
Forward P/E 33.7xFY2027 54.3xFY2026 31.4xFY2026
EPS, next fiscal year $2.16FY2027 $4.99FY2026 $5.10FY2026
EPS growth, next FY +11.9%FY2027 +3.1%FY2026 +0.8%FY2026
EPS growth, the year after +5.1% +25.7% +11.0%
Revenue, next fiscal year $1.19BFY2027 $4.52BFY2026 $2.98BFY2026
Revenue growth, next FY -2.1%FY2027 +4.1%FY2026 +4.0%FY2026
Revenue growth, the year after +13.5% +12.0% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTECHILMNRVTY
Held by institutions 100.0% 100.0% 100.0%
Institutions holding 597 933 545
Change in shares held, QoQ -0.6% +0.0% -1.3%
Institutions buying 293 463 301
Institutions selling 241 330 161
Buyers to sellers 1.22 1.40 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TECHILMNRVTY
TECH 1.00 0.22 0.45
ILMN 0.22 1.00 0.51
RVTY 0.45 0.51 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TECH, ILMN and RVTY?

Illumina (ILMN) is the largest by market capitalisation: Bio-Techne (TECH) $11.32B, Illumina (ILMN) $42.23B, Revvity (RVTY) $18.07B.

Which stock is cheaper, TECH, ILMN and RVTY?

Illumina (ILMN) trades on the lowest price-to-earnings ratio (Bio-Techne (TECH) 62.3x, Illumina (ILMN) 51.2x, Revvity (RVTY) 76.0x). On next year's consensus earnings, Revvity (RVTY) is cheapest (Bio-Techne (TECH) 33.7x, Illumina (ILMN) 54.3x, Revvity (RVTY) 31.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Illumina (ILMN) grew revenue fastest over the trailing twelve months: Bio-Techne (TECH) -0.4%, Illumina (ILMN) +4.9%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Bio-Techne (TECH) 15.0%, Illumina (ILMN) 18.4%, Revvity (RVTY) 8.2%). On return on invested capital, Illumina (ILMN) leads (Bio-Techne (TECH) 8.3%, Illumina (ILMN) 15.1%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Bio-Techne (TECH) +10.3%, Illumina (ILMN) +170.7%, Revvity (RVTY) +62.1%. Over five years, Revvity (RVTY) compounded fastest (Bio-Techne (TECH) -10.6%/yr, Illumina (ILMN) -7.5%/yr, Revvity (RVTY) -1.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Bio-Techne (TECH) has the highest dividend yield: Bio-Techne (TECH) 0.00%, Illumina (ILMN) 0.00%, Revvity (RVTY) 0.00%. Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Revvity (RVTY) has been the steadiest (Bio-Techne (TECH) 43.6%, Illumina (ILMN) 50.4%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TECH, ILMN and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Illumina (ILMN) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.